Canadian researchers on promising path towards developing flu treatment using lipid target
For most people, the influenza A virus (IAV), commonly known as the flu, is cleared from the body by our own immune system. In some cases, however, the immune response becomes dysregulated and if left uncontrolled, the inflammation caused by our own immune cells can lead to extensive lung tissue damage and enhanced morbidity and mortality.
How can we help our immune system to balance the two main host defense strategies: attacking pathogens (called host resistance) and preserving our own tissue (called disease tolerance)?
A team of scientists of the Research Institute of the 苹果淫院 Health Centre (RI-MUHC) in Montreal, Canada, has tackled this fundamental question and recently identified a target to 鈥渢one down鈥� the hyper-active immunity to influenza infection. They have identified a new role for the lipid mediator Leukotriene B4 (called LTB4) in the lung. In a study published in this week, they show that the LTB4 molecule is capable of not only reducing collateral tissue damage caused by immune responses but also enhancing host survival. These novel findings have promising clinical implications in the near future for the treatment of flu.
鈥淭he influenza virus is not the only threat; the host鈥檚 own immune response is mainly responsible for jeopardizing host survival,鈥� says first author of the study Dr. Erwan Pernet, who is a postdoctoral fellow in Dr. Maziar Divangahi鈥檚 laboratory at the RI-MUHC. 鈥淭herefore, it is essential to understand the regulatory mechanisms that maintain the tight balance between protective and harmful immunity.鈥�
A 鈥�lipid鈥� regulating the immune response
Influenza remains a global public health challenge, according to the World Health Organization. Each year, there are an estimated one billion people cases worldwide, resulting in 290,000 to 650,000 influenza-related respiratory deaths.
The root of this lung damage is associated with a subtype of immune cells called inflammatory monocyte-derived macrophages (IMM). While the recruitment of these specific macrophages to the site of infection is crucial to diminish viral replication, the uncontrolled accumulation of these cells is also responsible for the tissue damage.
Dr. Divangahi鈥檚 laboratory has focused on new immunotherapies targeting the immune system via host lipid mediators to either effectively kill the virus or limit lung tissue damage. In this study, they focused on the LTB4 lipid mediator and its effects on the immune response to flu infection.
After working with mice lacking the receptor for LTB4, they were able to identify a network of 鈥渞egulatory mechanisms that maintain the tight balance between protective and harmful immunity鈥� previously mentioned by Dr. Pernet.
鈥淔or the first time we show there is a subtype of macrophages in the lungs that are able to produce this immunoregulatory lipid (LTB4) to reduce the inflammation caused by another macrophage population that is responsible for causing lung tissue damage during influenza infection,鈥� explains lead author Dr. Maziar Divangahi, who is the Associate Director of the Meakins-Christie Laboratories and the Associate Director of the Translational Research in Respiratory Diseases Program at the RI-MUHC. He is also an associate professor of Medicine at 苹果淫院.
Of particular importance to future clinical studies was the finding that a single dose of LTB4 at the peak of disease was enough to significantly reduce lung immunopathology and tissue damage and improve host survival.
Based on this work, Dr. Divangahi and colleagues envision that 鈥淕iven the availability of a wide variety of drugs targeting lipid pathways (e.g. Aspirin) are already approved and used in humans for controlling the symptoms of infection or other immune diseases such as asthma, novel immunotherapy strategies targeting specific host lipid mediators have tremendous clinical implications for the treatment of influenza or potentially other viral infections.鈥�
听
"", by Erwan Pernet, Jeffrey Downey, Donald C. Vinh, William S. Powell, and Maziar Divangahi, was published in Nature Microbiology
This work was supported by a Foundation Grant. Dr. Divangahi holds a Award and the Strauss Chair in Respiratory Diseases. Dr. Pernet is supported by a Fonds de Recherche du Qu茅bec鈥揝ant茅 Fellowship.
About the Research Institute of the MUHC
The Research Institute of the 苹果淫院 Health Centre (RI-MUHC) is a world-renowned biomedical and healthcare research centre. The Institute, which is affiliated with the Faculty of Medicine of 苹果淫院, is the research arm of the 苹果淫院 Health Centre (MUHC) 鈥� an academic health centre located in Montreal, Canada, that has a mandate to focus on complex care within its community. The RI-MUHC supports over 460 researchers and close to 1,300 research trainees devoted to a broad spectrum of fundamental, clinical and health outcomes research at the Glen and the Montreal General Hospital sites of the MUHC. Its research facilities offer a dynamic multidisciplinary environment that fosters collaboration and leverages discovery aimed at improving the health of individual patients across their lifespan. The RI-MUHC is supported in part by the Fonds de recherche du Qu茅bec 鈥� Sant茅 (FRQS).
About 苹果淫院
Founded in Montreal, Que., in 1821, 苹果淫院 is Canada鈥檚 leading post-secondary institution. It has two campuses, 11 faculties, 11 professional schools, 300 programs of study and more than 37,000 students, including 8,300 graduate students. 苹果淫院 attracts students from over 150 countries around the world, with more than 7,200 international students making up 20 per cent of the student body. Almost half of 苹果淫院 students claim a first language other than English, including more than 6,200 Francophones.
